BOSTON, May 24 (Reuters) - GlaxoSmithKline Plc’s (GSK.L: Quote, Profile, Research) diabetes drug Avandamet, which is currently approved to treat patients who have failed certain alternative therapies, has received U.S. approval to be used in patients who have not received any treatment, the company said on Wednesday.
